Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

This phase 2, randomized, double blind trial evaluated the efficacy and safety of the nonpeptide GLP 1 receptor agonist orforglipron as a once daily oral therapy for weight reduction in adults with obesity or overweight with weight-related conditions. Participants (n=272) received orforglipron (12, 24, 36, or 45 mg) or placebo for 36 weeks. At week 26, mean weight reduction ranged from -8.6% to 12.6% with orforglipron versus -2.0% with placebo, improving further by week 36. A weight reduction of ≥10% occurred in 46–75% of orforglipron recipients versus 9% with placebo. Common adverse events were gastrointestinal (mild to moderate), with discontinuation rates of 10–17%. Orforglipron demonstrated efficacy and safety comparable to injectable GLP 1 agonists, offering a promising oral alternative for obesity management.

This phase 2, randomized, double blind trial evaluated the efficacy and safety of the nonpeptide GLP 1 receptor agonist orforglipron as a once daily oral therapy for weight reduction in adults with obesity or overweight with weight-related conditions. Participants (n=272) received orforglipron (12, 24, 36, or 45 mg) or placebo for 36 weeks. At week 26, mean weight reduction ranged from -8.6% to 12.6% with orforglipron versus -2.0% with placebo, improving further by week 36. A weight reduction of ≥10% occurred in 46–75% of orforglipron recipients versus 9% with placebo. Common adverse events were gastrointestinal (mild to moderate), with discontinuation rates of 10–17%. Orforglipron demonstrated efficacy and safety comparable to injectable GLP 1 agonists, offering a promising oral alternative for obesity management.